Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls

Wuhua Xu, Takeshi Kawarabayashi, Etsuro Matsubara, Kentaro Deguchi, Tetsuro Murakami, Yasuo Harigaya, Masaki Ikeda, Masakuni Amari, Ryozo Kuwano, Koji Abe, Mikio Shoji

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.

Original languageEnglish
Pages (from-to)169-179
Number of pages11
JournalBrain Research
Volume1219
DOIs
Publication statusPublished - Jul 11 2008

Fingerprint

Amyloid Plaques
Alzheimer Disease
Antibodies
Serum Amyloid A Protein
Active Immunotherapy
Immune Tolerance
Immunotherapy
Transgenic Mice
Brain

Keywords

  • Alzheimer's disease
  • Amyloid
  • Antibodies
  • Plasma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Xu, W., Kawarabayashi, T., Matsubara, E., Deguchi, K., Murakami, T., Harigaya, Y., ... Shoji, M. (2008). Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls. Brain Research, 1219, 169-179. https://doi.org/10.1016/j.brainres.2008.02.060

Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls. / Xu, Wuhua; Kawarabayashi, Takeshi; Matsubara, Etsuro; Deguchi, Kentaro; Murakami, Tetsuro; Harigaya, Yasuo; Ikeda, Masaki; Amari, Masakuni; Kuwano, Ryozo; Abe, Koji; Shoji, Mikio.

In: Brain Research, Vol. 1219, 11.07.2008, p. 169-179.

Research output: Contribution to journalArticle

Xu, W, Kawarabayashi, T, Matsubara, E, Deguchi, K, Murakami, T, Harigaya, Y, Ikeda, M, Amari, M, Kuwano, R, Abe, K & Shoji, M 2008, 'Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls', Brain Research, vol. 1219, pp. 169-179. https://doi.org/10.1016/j.brainres.2008.02.060
Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y et al. Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls. Brain Research. 2008 Jul 11;1219:169-179. https://doi.org/10.1016/j.brainres.2008.02.060
Xu, Wuhua ; Kawarabayashi, Takeshi ; Matsubara, Etsuro ; Deguchi, Kentaro ; Murakami, Tetsuro ; Harigaya, Yasuo ; Ikeda, Masaki ; Amari, Masakuni ; Kuwano, Ryozo ; Abe, Koji ; Shoji, Mikio. / Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls. In: Brain Research. 2008 ; Vol. 1219. pp. 169-179.
@article{5b546676eff64f9e924de75aeb6cc49d,
title = "Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls",
abstract = "Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1{\%}) and age-matched controls (41.2{\%}), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.",
keywords = "Aβ, Alzheimer's disease, Amyloid, Antibodies, Plasma",
author = "Wuhua Xu and Takeshi Kawarabayashi and Etsuro Matsubara and Kentaro Deguchi and Tetsuro Murakami and Yasuo Harigaya and Masaki Ikeda and Masakuni Amari and Ryozo Kuwano and Koji Abe and Mikio Shoji",
year = "2008",
month = "7",
day = "11",
doi = "10.1016/j.brainres.2008.02.060",
language = "English",
volume = "1219",
pages = "169--179",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls

AU - Xu, Wuhua

AU - Kawarabayashi, Takeshi

AU - Matsubara, Etsuro

AU - Deguchi, Kentaro

AU - Murakami, Tetsuro

AU - Harigaya, Yasuo

AU - Ikeda, Masaki

AU - Amari, Masakuni

AU - Kuwano, Ryozo

AU - Abe, Koji

AU - Shoji, Mikio

PY - 2008/7/11

Y1 - 2008/7/11

N2 - Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.

AB - Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.

KW - Aβ

KW - Alzheimer's disease

KW - Amyloid

KW - Antibodies

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=45849141567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849141567&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2008.02.060

DO - 10.1016/j.brainres.2008.02.060

M3 - Article

C2 - 18534566

AN - SCOPUS:45849141567

VL - 1219

SP - 169

EP - 179

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -